AMENDMENT TO THE RESEARCH AND DEVELOPMENT AGREEMENT
THE BRIGHAM AND WOMEN’S HOSPITAL, INC. AND AUTOIMMUNE, INC.
This Amendment to the Research and Development Agreement (“Amendment”) between The Brigham and Women’s Hospital,
Inc. (“BWH”) and AutoImmune, Inc. (“Company”) is effective July 1, 2003. The BWH and the Company are parties to a
Research and Development Agreement effective September 9, 1988, as amended and restated on July 1, 1992, April 14, 1995, July
1, 2000, July 1, 2001 and July 1, 2002 (“Agreement”), pursuant to which the BWH agreed to conduct certain scientific research in
consideration of the payment of certain fees by the Company.
BWH and Company now wish to amend certain provisions of the Agreement, and in consideration of the promises and
agreements set forth herein, and for other good and valuable consideration, the BWH and Company hereby agree as follows:
$12,000 due upon execution of this Amendment;
$12,000 due October 1, 2002;
$12,000 due January 1, 2003;
$12,000 due April 1, 2003
Except as expressly modified above, all obligations in the Agreement remain in full force and effect.
The term of the Agreement will be extended to June 30, 2004, and shall be renewable for additional one year periods by
mutual written consent upon the submission and acceptance of a new Research Program definition and Budget for each
such extension, unless terminated as provided in the Agreement.
The scope of the Research Program for the twelve months ending June 30, 2004 is as set forth in Appendix A1 to this
For such Research Program, the Company shall pay $48,000 as provided in the Budget attached as Appendix B1.
Notwithstanding the provisions of Section 11.1(b) of the Agreement, the Budget is payable in equal installments due on
the following dates:
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their duly authorized
representatives effective as of the first